Hu Wei-Syun, Lin Cheng-Li
School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, 2, Yuh-Der Road, Taichung, 40447, Taiwan.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):581-589. doi: 10.1007/s00210-024-03296-0. Epub 2024 Jul 20.
The objective was to assess the protective role of anti-diabetic agent (ADA) in predicting interstitial lung disease (ILD) among patients with diabetes mellitus (DM). We formed a cohort of DM patients between 2009 and 2016 using data from Taiwan. Univariable and multivariable Cox proportion hazards regression models were used to examine the effect of risk factor on the risk of developing ILD, presented as a hazard ratio (HR) with a 95% confidence interval (CI). Cox proportional hazard regression analysis for the risk of DM-associated ILD with joint effect of dipeptidyl peptidase-4 inhibitor (DPP4I), glucagon-like peptide-1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter 2 inhibitors (SGLT2I) showed that SGLT2I, GLP-1 RA, and DPP-4I had a decreased risk of ILD with adjusted HR of 0.14 (0.11, 0.18), 0.29 (0.24, 0.35), and 0.64 (0.62, 0.67), respectively. DPP4I, GLP-1 RA, and SGLT2I could be considered to be introduced to this DM population for ILD risk reduction in DM, especially with SGLT2I usage.
目的是评估抗糖尿病药物（ADA）在预测糖尿病（DM）患者间质性肺疾病（ILD）方面的保护作用。我们利用台湾的数据，在2009年至2016年间组建了一个DM患者队列。使用单变量和多变量Cox比例风险回归模型来检验风险因素对发生ILD风险的影响，以风险比（HR）和95%置信区间（CI）表示。对二肽基肽酶-4抑制剂（DPP4I）、胰高血糖素样肽-1受体激动剂（GLP-1 RA）和钠-葡萄糖协同转运蛋白2抑制剂（SGLT2I）联合作用导致的DM相关ILD风险进行Cox比例风险回归分析，结果显示SGLT2I、GLP-1 RA和DPP-4I发生ILD的风险降低，调整后的HR分别为0.14（0.11，0.18）、0.29（0.24，0.35）和0.64（0.62，0.67）。DPP4I、GLP-1 RA和SGLT2I可考虑引入该DM人群以降低DM患者发生ILD的风险，尤其是使用SGLT2I时。
